Histology and Cytology Market Size, Share & Trends Analysis Report By Type of Examination (Cytology [Cervical Cancer, Breast Cancer], Histology), By Region, And Segment Forecasts, 2019 - 2026

Industry Insights

The global histology and cytology market size was valued at USD 11.0 billion in 2018 and is estimated to expand at a CAGR of around 13.7% over the forecast period. High prevalence of cancer and continuous R&D are expected to be the key factors driving the growth. Technological advancements and investments in innovation are projected to further fuel the expansion.

According to the World Health Organization (WHO), cancer was the second leading cause of death across the globe and was responsible for 8.8 million deaths in 2015. Hence, the high incidence of cancer due to changing lifestyle and change in environment are likely to drive the market during the forecast period.

Furthermore, growing awareness about the screening of cancer and technological advancements in the cell and tissue studies are likely to boost the demand in near future. The requirement of companion diagnostics for targeted drugs is likely to drive the demand for cytology and histology products in the forthcoming years.

Continuous R&D efforts by major players widen the scope of application for diagnosis of various diseases. This factor is likely to drive the market. Presently, the tests are majorly used for the screening of cervical and breast cancer. However, adoption of these tests for the screening of bladder and lung cancer is growing at rapid rate.

Type of Examination Insights

Based on type of examination, the market has been segmented into cytology and histology. Cytology is further segmented by application into cervical, breast, and other cancers. In 2018, segment held the highest market share, attributed to higher demand for cell screening. Advantages such as low cost, high specificity, and adequate sensitivity bode well for segment growth.

Cervix and breast screening are the major applications of cytology. Cervical cancer accounted for the largest market share in 2018 and is expected to maintain its dominance during the forecast period. This can be attributed to large patient pool and availability of products for the cervical cancer screening.

Other cancer majorly includes cancer of urinary bladder, lungs, head and neck, colorectal, and ovary. Furthermore, the scope of application is continuously on the rise due to ongoing research in the field. Investments by major players for the development and commercialization of tests is likely to drive the other cancers screening segment over the forecast period.

Regional Insights

Asia Pacific is expected to be the fastest growing region over the forecast period. India, China, and Singapore have been experiencing strong economic growth and are the major emerging countries in this region. Growing geriatric population, prevalence of cancer, and awareness about cancer screening are likely to drive the growth. Japan contributed the highest share in Asia Pacific owing to higher affordability and awareness about overall health among patients.

North America led the global histology and cytology market in 2018. Availability of well-equipped diagnostic clinics, better coverage for diagnosis and treatment, and government initiatives for the implementation of high-quality screening are the factors responsible for the dominance of the region.

Europe accounted for a significant market share in 2018 due to the presence of major market players and affordability of the tests among the regional patients. Furthermore, growing incidence of cancer in Europe and recent product approvals are likely to drive the regional market growth in the forthcoming years.

Histology and Cytology Market Share Insights

The global market is highly competitive in nature. Major players are Abbott Laboratories; Becton, Dickinson and Company; Danaher; F. Hoffmann-La Roche Ltd; Hologic, Inc.; Sysmex Corporation; Thermo Fisher Scientific, Inc.; and Trivitron Healthcare.

Development of sensitive and specific products and targeted commercialization activities by mergers or collaborations are the key parameters to remain competitive and to gain greater market share. For instance, in April 2017 Roche CINtec Histology test received the Food and Drug Administration (FDA) approval and is expected to improve consistency in the diagnosis of cervical-pre cancers.

In September 2018, Phillips launched computational pathology software, TissueMark, for automated ovarian and prostate tumor detection. This newer version was showcased at the 30th European Congress of Pathology (ECP) 2018. TissueMark helps laboratories to improve tumor detection accuracy.

In July 2017, Sysmex Corporation announced the expansion of its reagent factory in U.S. The reagent production capacity is expected to increase 1.8 times in response to the expected rise in demand from the Americas.

In 2015, Hologic, Inc. launched its two new processors that provide access to the next generation in cytology slide processing. Hence, product development and commercialization is a key strategy to be competitive in the market.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global histology and cytology market report based on type of examination and region:

• Type of Examination Outlook (Revenue, USD Million, 2015 - 2026)

  • Cytology

    • Cervical Cancer

    • Breast Cancer

    • Other Cancers

  • Histology

• Regional Outlook (Revenue, USD Million, 2015 - 2026)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa